|
A.P. Pharma wants to hit you where it hurts. The firm develops bioerodible polymers for injectable and implantable drug delivery. Its Biochronomer technology delivers medication directly to the site where the drug is needed. A.P. Pharma's leading drug candidate, APF530, could ease chemotherapy-induced nausea and vomiting. A second candidate in clinical trials is a post-surgical pain management product that delivers pain relief right to the surgical site. A.P. Pharma is also developing therapies for inflammation and chronic pain using its Biochronomer technology. Its drug candidates combine approved therapeutics with its bioerodible polymers.
|
| | | Contact Information | |
Address: |
123 Saginaw Dr.
Redwood City, CA 94063
| | Phone: | 650-366-2626 | | Fax: | 650-365-6490 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 0.40 M | | Revenue Growth (1 yr): | (-10.40%) | | Employees (2008): | 33 | | Employee Growth (1 yr): | (-25.00%) |
|
|
Key People
| | • |
Chairman:
Paul Goddard
| | • |
President, CEO, and Director:
Ronald J. (Ron) Prentki
| | • |
VP Finance and CFO:
John B. Whelan
|
|
|
